Efficacy of the combined use of GLP-1 receptor agonists with lifestyle modification in patients with type 2 diabetes mellitus and insulin resistance: a clinical case

Antsiferova D.M., Koteshkova O.M., Romashkina L.P., Antsiferov M.B.

1) Endocrinology Dispensary, Moscow Healthcare Department, Russia; 2) Russian Medical Academy of Continuous Professional Education, Moscow, Russia

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are prescribed for the most effective treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, especially in cases where dietary changes and increased physical activity are insufficient. As the use of this class of drugs expands, concerns about the adverse effects of weight loss, including uncontrolled muscle loss, are growing, which is particularly relevant for patients with morbid obesity and severe insulin resistance.
This article highlights the importance of combining GLP-1 RA with a balanced diet and physical activity in the treatment of T2DM. It examines barriers to adherence to dietary recommendations and regular exercise, and provides practical advice for physicians on additional education and counseling of patients on these aspects when initiating GLP-1 RA treatment.

For citations: Antsiferova D.M., Koteshkova O.M., Romashkina L.P., Antsiferov M.B. Efficacy of the combined use of GLP-1 receptor agonists with lifestyle modification in patients with type 2 diabetes mellitus and insulin resistance: a clinical case. Pharmateca. 2026;33(2):127-134. (In Russ.). DOI: https://dx.doi.org/10.18565/pharmateca.2026.2.127-134

Authors’ contribution: . M.B. Antsiferov – article design, manuscript approval. O.M. Koteshkova – review of relevant publications, manuscript writing, case report. D.M. Antsiferova – – review of publications on the topic of the article, writing the manuscript, and describing the clinical case. L.P. Romashkina – writing the manuscript.
Conflicts of interest: The authors confirm that they have no conflicts of interest to declare.
Funding: The study was conducted without any sponsorship.
Patient Consent for Publication: The patients provided an informed consent for the publication of their data.

Keywords

About the Authors

Daria M. Antsiferova, Endocrinologist, Endocrinology Dispensary, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia; Postgraduate Student, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia;
cifrenda@yandex.ru, ORCID: https://orcid.org/0000-0002-3920-5914, eLibrary SPIN: 5461-2590
Olga M. Koteshkova, Cand. Sci. (Med.), Head of the Department of Diabetes Education and Treatment, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia; koala58@mail.ru, ORCID: https://orcid.org/0000-0001-8428-4116, eLibrary SPIN: 6141-1224 (corresponding author)
L.P. Romashkina, Endocrinology Dispensary, Endocrinology Dispensary, Moscow Healthcare Department, Moscow, Russia
Mikhail B. Antsiferov, Dr. Sci. (Med.), Professor, President, Endocrinology Dispensary, Moscow Healthcare Department; Professor, Department of Endocrinology, Russian Medical Academy of Continuous Professional Education, Moscow, Russia; antsiferov@rambler.ru, ORCID: https://orcid.org/0000-0002-9944-2997, eLibrary SPIN: 1035-4773

Similar Articles